TORL-1-23

DRUG3 trials

Sponsors

Torl Biotherapeutics LLC, TORL Biotherapeutics, LLC

Conditions

Advanced Solid TumorEndometrial CancerEndometrioid Ovarian CancerEpithelial Ovarian CancerFallopian Tube CancerNSCLCOvarian CancerPeritoneal Cancer

Phase 1

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

RecruitingNCT05103683

TORL Biotherapeutics, LLCAdvanced Solid Tumor, Endometrial Cancer, NSCLC +1

Start: 2021-11-17End: 2026-11-15Target: 90Updated: 2026-02-13

Phase 2

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

RecruitingNCT06690775

TORL Biotherapeutics, LLCEndometrioid Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer +1

Start: 2024-11-20End: 2027-12-31Target: 230Updated: 2025-12-23

CATALINA-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (CLDN6)

RecruitingCTIS2024-517190-24-00

Torl Biotherapeutics LLCFallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer

Start: 2025-09-16Target: 159Updated: 2026-01-25

Related Papers

PR062/#686 First-in-human phase 1 study of torl-1–23, a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) in patients with ovarian cancer

2023-11-01

Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.

Journal of Clinical Oncology2023-06-0112 citations